New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
16:08 EDTNVAXNovavax files automatic mixed securities shelf
News For NVAX From The Last 14 Days
Check below for free stories on NVAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
16:09 EDTNVAXNovavax initiates Phase 2 trial of RSV F vaccine candidate
Subscribe for More Information
September 7, 2014
12:31 EDTNVAXNovavax presents data on RSV F nanoparticle vaccine induced monoclonal antibody
Novavax presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab, Syangis, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, in Washington, DC. In poster session 024: I-314b titled "Development and Characterization of Recombinant RSV Nanoparticle Vaccine Induced Monoclonal Antibody.", Novavax used its RSV F vaccine to generate a murine monoclonal antibody, NVX4C6, that binds to the antigenic site II on the RSV F-protein. Using Surface Plasmon Resonance, Novavax was able to compare the binding affinity of NVX4C6 and palivizumab to the antigenic site II. This experiment demonstrated that Novavax' RSV F vaccine can induce antibodies to the antigenic site II that have a higher binding affinity to the site than palivizumab. In addition, NVX4C6 was shown to have a slightly different specificity to the site II epitope and to recognize mutated site II peptide not recognized by palivizumab, suggesting that NVX4C6 may neutralize palivizumab escape mutants.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use